Stocksigma LogoStocksigma Logo

Kwality Pharmaceuticals Posts Robust Q2 FY27 Growth and Appoints BSR as Auditor

Kwality Pharmaceuticals reported strong Q2 FY27 results, with consolidated revenue surging 63% YoY to ₹181 crore and PAT doubling YoY to ₹50 crore

Kwality Pharmaceuticals Posts Robust Q2 FY27 Growth and Appoints BSR as Auditor

Kwality Pharmaceuticals Ltd · Change in Auditor · 12 Nov 2026, 6:35 pm

Kwality Pharmaceuticals Posts Robust Q2 FY27 Growth and Appoints BSR as Auditor Kwality Pharmaceuticals reported strong Q2 FY27 results, with consolidated revenue surging 63% YoY to ₹181 crore and PAT doubling YoY to ₹50 crore. EBITDA margin expanded to 27.5% from 23.4% in Q2 FY26. Consequently, management raised its FY27 revenue guidance to ₹720+ crore from ₹700 crore. Additionally, the company acquired 4 acres in Amritsar for Unit 7, secured Hungarian EU-GMP certification, and appointed B S R & Co. LLP as statutory auditor on 12th Nov'26 to fill the casual vacancy following Vijay Mehra & Co.'s resignation.

Original exchange filing (PDF)

More announcements from Kwality Pharmaceuticals Ltd

All Kwality Pharmaceuticals Ltd announcements